A novel combinatorial strategy using Seliciclib(®) and Belinostat(®) for eradication of non-small cell lung cancer via apoptosis induction and BID activation. [electronic resource]
Producer: 20170728Description: 49-57 p. digitalISSN:- 1872-7980
- A549 Cells
- Antineoplastic Combined Chemotherapy Protocols -- pharmacology
- Apoptosis -- drug effects
- BH3 Interacting Domain Death Agonist Protein -- agonists
- Carcinoma, Non-Small-Cell Lung -- drug therapy
- Caspase 3 -- metabolism
- Caspase 8 -- metabolism
- Caspase Inhibitors -- pharmacology
- Cell Proliferation -- drug effects
- Dose-Response Relationship, Drug
- Histone Deacetylase Inhibitors -- pharmacology
- Humans
- Hydroxamic Acids -- pharmacology
- Inhibitory Concentration 50
- Lung Neoplasms -- drug therapy
- Myeloid Cell Leukemia Sequence 1 Protein -- metabolism
- Poly(ADP-ribose) Polymerases -- metabolism
- Protein Kinase Inhibitors -- pharmacology
- Purines -- pharmacology
- RNA Interference
- Roscovitine
- Signal Transduction -- drug effects
- Sulfonamides -- pharmacology
- Time Factors
- Transfection
- Tumor Suppressor Protein p53 -- metabolism
- X-Linked Inhibitor of Apoptosis Protein -- metabolism
No physical items for this record
Publication Type: Journal Article
There are no comments on this title.
Log in to your account to post a comment.